This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dyax Corp. Announces Five HAE Allies℠ Honorees, Underscoring Critical Role Of Support For Patients With Hereditary Angioedema

“A support network is essential to those living with HAE,” stated Gustav Christensen, President and Chief Executive Officer of Dyax. “These honorees truly exemplify the meaningful difference individuals can make for someone struggling with a rare disease.”

In addition to recognizing a group of honorees who have demonstrated extraordinary commitment to a specific HAE patient or the HAE community in general, the goal of the HAE Allies program is to utilize insights from the submissions to empower more patients to seek and receive the support they need from their healthcare providers, families and communities.

“As a nurse for over 35 years, I have dedicated my life to helping people get the treatment and support they need to manage illness. HAE presents unique challenges because of the unpredictability of attacks and the lack of awareness of the condition,” said Barbara Mathews, RN and HAE Allies honoree. “In my role as a nurse I’ve had the privilege to partner with patients to help navigate some of these hurdles, hopefully enabling them to more easily work, travel, or participate in activities they enjoy. I have been truly awed by the optimism and tenacity of those facing this condition.”

About HAE

Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect up to 1 in 50,000 individuals. Learn more at  www.HAEHope.com/HAEAllies.

About KALBITOR

KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR, which was discovered and developed by Dyax, is the first subcutaneous treatment available in the U.S. for treating acute HAE attacks.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs